TY - JOUR AU - Herbst, R. S. AU - Heymach, J. V. AU - Lippman, S. M. PY - 2008 DA - 2008// TI - Lung cancer JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMra0802714 DO - 10.1056/NEJMra0802714 ID - Herbst2008 ER - TY - JOUR AU - Mok, T. S. AU - Wu, Y. AU - Thongprasert, S. AU - Yang, C. AU - Saijo, N. AU - Sunpaweravong, P. PY - 2009 DA - 2009// TI - Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0810699 DO - 10.1056/NEJMoa0810699 ID - Mok2009 ER - TY - JOUR AU - Wu, Y. -. L. AU - Zhou, C. AU - Hu, C. -. P. AU - Feng, J. AU - Lu, S. AU - Huang, Y. PY - 2014 DA - 2014// TI - Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(13)70604-1 DO - 10.1016/S1470-2045(13)70604-1 ID - Wu2014 ER - TY - JOUR AU - Inoue, A. AU - Suzuki, T. AU - Fukuhara, T. AU - Maemondo, M. AU - Kimura, Y. AU - Morikawa, N. PY - 2006 DA - 2006// TI - Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.05.4692 DO - 10.1200/JCO.2005.05.4692 ID - Inoue2006 ER - TY - JOUR AU - Riely, G. J. AU - Politi, K. A. AU - Miller, V. A. AU - Pao, W. PY - 2006 DA - 2006// TI - Update on epidermal growth factor receptor mutations in non-small cell lung cancer JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-06-0658 DO - 10.1158/1078-0432.CCR-06-0658 ID - Riely2006 ER - TY - JOUR AU - Mok, T. S. AU - Wu, Y. -. L. AU - Ahn, M. -. J. AU - Garassino, M. C. AU - Kim, H. R. AU - Ramalingam, S. S. PY - 2017 DA - 2017// TI - Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMoa1612674 DO - 10.1056/NEJMoa1612674 ID - Mok2017 ER - TY - JOUR AU - Bylicki, O. AU - Ferlay, C. AU - Chouaid, C. AU - Lavolé, A. AU - Barlési, F. AU - Dubos, C. PY - 2013 DA - 2013// TI - Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study JO - J Thorac Oncol VL - 8 UR - https://doi.org/10.1097/JTO.0b013e31828cb505 DO - 10.1097/JTO.0b013e31828cb505 ID - Bylicki2013 ER - TY - JOUR AU - Yu, H. A. AU - Arcila, M. E. AU - Rekhtman, N. AU - Sima, C. S. AU - Zakowski, M. F. AU - Pao, W. PY - 2014 DA - 2014// TI - Analysis of tumor specimens at the time of acquired resistance to EGFR TKI therapy in 155 patients with EGFR mutant lung cancers JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-2246 DO - 10.1158/1078-0432.CCR-12-2246 ID - Yu2014 ER - TY - JOUR AU - Oxnard, G. R. AU - Arcila, M. E. AU - Chmielecki, J. AU - Ladanyi, M. AU - Miller, V. A. AU - Pao, W. PY - 2011 DA - 2011// TI - New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-10-2571 DO - 10.1158/1078-0432.CCR-10-2571 ID - Oxnard2011 ER - TY - JOUR AU - Socinski, M. A. AU - Villaruz, L. C. AU - Ross, J. PY - 2017 DA - 2017// TI - Understanding mechanisms of resistance in the epithelial growth factor receptor in non-small cell lung cancer and the role of biopsy at progression JO - Oncologist VL - 22 UR - https://doi.org/10.1634/theoncologist.2016-0285 DO - 10.1634/theoncologist.2016-0285 ID - Socinski2017 ER - TY - JOUR AU - Yano, S. AU - Yamada, T. AU - Takeuchi, S. AU - Tachibana, K. AU - Minami, Y. AU - Yatabe, Y. PY - 2011 DA - 2011// TI - Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a japanese cohort JO - J Thorac Oncol VL - 6 UR - https://doi.org/10.1097/JTO.0b013e31823ab0dd DO - 10.1097/JTO.0b013e31823ab0dd ID - Yano2011 ER - TY - JOUR AU - Bean, J. AU - Brennan, C. AU - Shih, J. -. Y. AU - Riely, G. AU - Viale, A. AU - Wang, L. PY - 2007 DA - 2007// TI - MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib JO - Proc Nati Acad Sci USA VL - 104 UR - https://doi.org/10.1073/pnas.0710370104 DO - 10.1073/pnas.0710370104 ID - Bean2007 ER - TY - JOUR AU - Takezawa, K. AU - Pirazzoli, V. AU - Arcila, M. E. AU - Nebhan, C. A. AU - Song, X. AU - Stanchina, E. PY - 2012 DA - 2012// TI - HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR T790M mutation JO - Cancer Discov VL - 2 UR - https://doi.org/10.1158/2159-8290.CD-12-0108 DO - 10.1158/2159-8290.CD-12-0108 ID - Takezawa2012 ER - TY - JOUR AU - Erjala, K. AU - Sundvall, M. AU - Junttila, T. T. AU - Zhang, N. AU - Savisalo, M. AU - Mali, P. PY - 2006 DA - 2006// TI - Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-05-2404 DO - 10.1158/1078-0432.CCR-05-2404 ID - Erjala2006 ER - TY - JOUR AU - Lee, Y. AU - Wang, Y. AU - James, M. AU - Jeong, J. H. AU - You, M. PY - 2016 DA - 2016// TI - Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells JO - Mol Carcinog VL - 55 UR - https://doi.org/10.1002/mc.22342 DO - 10.1002/mc.22342 ID - Lee2016 ER - TY - JOUR AU - Taniguchi, H. AU - Yamada, T. AU - Wang, R. AU - Tanimura, K. AU - Adachi, Y. AU - Nishiyama, A. PY - 2019 DA - 2019// TI - AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells JO - Nat Commun VL - 10 UR - https://doi.org/10.1038/s41467-018-08074-0 DO - 10.1038/s41467-018-08074-0 ID - Taniguchi2019 ER - TY - JOUR AU - Tan, C. S. AU - Gilligan, D. AU - Pacey, S. PY - 2015 DA - 2015// TI - Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00246-6 DO - 10.1016/S1470-2045(15)00246-6 ID - Tan2015 ER - TY - JOUR AU - Soria, J. -. C. AU - Ohe, Y. AU - Vansteenkiste, J. AU - Reungwetwattana, T. AU - Chewaskulyong, B. AU - Lee, K. H. PY - 2018 DA - 2018// TI - Osimertinib in untreated EGFR -mutated advanced non–small-cell lung cancer JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1713137 DO - 10.1056/NEJMoa1713137 ID - Soria2018 ER - TY - JOUR AU - Minari, R. AU - Bordi, P. AU - Tiseo, M. PY - 2017 DA - 2017// TI - Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance JO - Transl Lung Cancer Res VL - 5 UR - https://doi.org/10.21037/tlcr.2016.12.02 DO - 10.21037/tlcr.2016.12.02 ID - Minari2017 ER - TY - JOUR AU - Nagano, T. AU - Tachihara, M. AU - Nishimura, Y. PY - 2018 DA - 2018// TI - Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy JO - Cells VL - 7 UR - https://doi.org/10.3390/cells7110212 DO - 10.3390/cells7110212 ID - Nagano2018 ER - TY - JOUR AU - Oxnard, G. R. AU - Hu, Y. AU - Mileham, K. F. AU - Husain, H. AU - Costa, D. B. AU - Tracy, P. PY - 2018 DA - 2018// TI - Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M–positive lung cancer and acquired resistance to Osimertinib JO - JAMA Oncol VL - 4 UR - https://doi.org/10.1001/jamaoncol.2018.2969 DO - 10.1001/jamaoncol.2018.2969 ID - Oxnard2018 ER - TY - JOUR AU - Schaller, M. D. AU - Borgman, C. A. AU - Cobb, B. S. AU - Vines, R. R. AU - Reynoldst, A. B. AU - Parsons, J. T. PY - 1992 DA - 1992// TI - pp125FAK, a structurally distinctive protein-tyrosine kinase associated with focal adhesions JO - Proc Nati Acad Sci USA VL - 89 UR - https://doi.org/10.1073/pnas.89.11.5192 DO - 10.1073/pnas.89.11.5192 ID - Schaller1992 ER - TY - JOUR AU - Parsons, J. T. PY - 2003 DA - 2003// TI - Focal adhesion kinase: the first ten years JO - J Cell Sci VL - 116 UR - https://doi.org/10.1242/jcs.00373 DO - 10.1242/jcs.00373 ID - Parsons2003 ER - TY - JOUR AU - Aboubakar Nana, F. AU - Lecocq, M. AU - Ladjemi, M. Z. AU - Detry, B. AU - Dupasquier, S. AU - Feron, O. PY - 2019 DA - 2019// TI - Therapeutic potential of focal adhesion kinase inhibition in small cell lung cancer JO - Mol Cancer Ther VL - 18 UR - https://doi.org/10.1158/1535-7163.MCT-18-0328 DO - 10.1158/1535-7163.MCT-18-0328 ID - Aboubakar Nana2019 ER - TY - JOUR AU - Zhao, J. AU - Guan, J. L. PY - 2009 DA - 2009// TI - Signal transduction by focal adhesion kinase in cancer JO - Cancer Metastasis Rev VL - 28 UR - https://doi.org/10.1007/s10555-008-9165-4 DO - 10.1007/s10555-008-9165-4 ID - Zhao2009 ER - TY - JOUR AU - Howe, G. A. AU - Xiao, B. AU - Zhao, H. AU - Al-Zahrani, K. N. AU - Hasim, M. S. AU - Villeneuve, J. PY - 2016 DA - 2016// TI - Focal adhesion kinase inhibitors in combination with erlotinib demonstrate enhanced anti-tumor activity in non-small cell lung cancer JO - PLoS One VL - 11 UR - https://doi.org/10.1371/journal.pone.0150567 DO - 10.1371/journal.pone.0150567 ID - Howe2016 ER - TY - JOUR AU - Kang, Y. AU - Hu, W. AU - Ivan, C. AU - Dalton, H. J. AU - Miyake, T. AU - Pecot, C. V. PY - 2013 DA - 2013// TI - Role of focal adhesion kinase in regulating YB – 1 – mediated paclitaxel resistance in ovarian cancer JO - J Natl Cancer Inst VL - 105 UR - https://doi.org/10.1093/jnci/djt210 DO - 10.1093/jnci/djt210 ID - Kang2013 ER - TY - JOUR AU - Sulzmaier, F. J. AU - Jean, C. AU - Schlaepfer, D. D. PY - 2014 DA - 2014// TI - FAK in cancer: mechanistic findings and clinical applications JO - Nat Rev Cancer VL - 14 UR - https://doi.org/10.1038/nrc3792 DO - 10.1038/nrc3792 ID - Sulzmaier2014 ER - TY - JOUR AU - Golubovskaya, V. PY - 2014 DA - 2014// TI - Targeting FAK in human cancer: from finding to first clinical trials JO - Front Biosci VL - 19 UR - https://doi.org/10.2741/4236 DO - 10.2741/4236 ID - Golubovskaya2014 ER - TY - JOUR AU - Lee, B. Y. AU - Timpson, P. AU - Horvath, L. G. AU - Daly, R. J. PY - 2015 DA - 2015// TI - FAK signaling in human cancer as a target for therapeutics JO - Pharmacol Ther VL - 146 UR - https://doi.org/10.1016/j.pharmthera.2014.10.001 DO - 10.1016/j.pharmthera.2014.10.001 ID - Lee2015 ER - TY - JOUR AU - Tanino, R. AU - Tsubata, Y. AU - Harashima, N. AU - Harada, M. AU - Isobe, T. PY - 2018 DA - 2018// TI - Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer JO - Oncotarget VL - 9 UR - https://doi.org/10.18632/oncotarget.24704 DO - 10.18632/oncotarget.24704 ID - Tanino2018 ER - TY - JOUR AU - Tomayko, M. M. AU - Reynolds, C. P. PY - 1989 DA - 1989// TI - Determination of subcutaneous tumor size in athymic (nude) mice JO - Cancer Chemother Pharmacol VL - 24 UR - https://doi.org/10.1007/BF00300234 DO - 10.1007/BF00300234 ID - Tomayko1989 ER - TY - JOUR AU - Sápi, J. AU - Kovács, L. AU - Drexler, D. A. AU - Kocsis, P. AU - Gajári, D. AU - Sápi, Z. PY - 2015 DA - 2015// TI - Tumor volume estimation and quasi- continuous administration for most effective bevacizumab therapy JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0142190 DO - 10.1371/journal.pone.0142190 ID - Sápi2015 ER - TY - JOUR AU - Sonoda, Y. AU - Watanabe, S. AU - Matsumoto, Y. AU - Aizu-Yokota, E. AU - Kasahara, T. PY - 1999 DA - 1999// TI - FAK is the upstream signal protein of the phosphatidylinositol 3- kinase-Akt survival pathway in hydrogen peroxide-induced apoptosis of a human glioblastoma cell line JO - J Biol Chem VL - 274 UR - https://doi.org/10.1074/jbc.274.15.10566 DO - 10.1074/jbc.274.15.10566 ID - Sonoda1999 ER - TY - JOUR AU - Yoon, H. AU - Dehart, J. P. AU - Murphy, J. M. AU - Lim, S. T. S. PY - 2015 DA - 2015// TI - Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights JO - J Histochem Cytochem VL - 63 UR - https://doi.org/10.1369/0022155414561498 DO - 10.1369/0022155414561498 ID - Yoon2015 ER - TY - JOUR AU - Siesser, P. M. F. AU - Hanks, S. K. PY - 2006 DA - 2006// TI - The signaling and biological implications of FAK overexpression in cancer JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-06-0456 DO - 10.1158/1078-0432.CCR-06-0456 ID - Siesser2006 ER - TY - JOUR AU - Carelli, S. AU - Zadra, G. AU - Vaira, V. AU - Falleni, M. AU - Bottiglieri, L. AU - Nosotti, M. PY - 2006 DA - 2006// TI - Up-regulation of focal adhesion kinase in non-small cell lung cancer JO - Lung Cancer VL - 53 UR - https://doi.org/10.1016/j.lungcan.2006.06.001 DO - 10.1016/j.lungcan.2006.06.001 ID - Carelli2006 ER - TY - JOUR AU - Canel, M. AU - Secades, P. AU - Rodrigo, J. P. AU - Cabanillas, R. AU - Herrero, A. AU - Suarez, C. PY - 2006 DA - 2006// TI - Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-05-1583 DO - 10.1158/1078-0432.CCR-05-1583 ID - Canel2006 ER - TY - JOUR AU - Golubovskaya, V. M. AU - Conway-Dorsey, K. AU - Edmiston, S. N. AU - Tse, C. K. AU - Lark, A. A. AU - Livasy, C. A. PY - 2009 DA - 2009// TI - FAK overexpression and p53 mutations are highly correlated in human breast cancer JO - Int J Cancer VL - 125 UR - https://doi.org/10.1002/ijc.24486 DO - 10.1002/ijc.24486 ID - Golubovskaya2009 ER - TY - JOUR AU - Fang, X. AU - Liu, X. AU - Yao, L. AU - Chen, C. AU - Lin, J. AU - Ni, P. PY - 2014 DA - 2014// TI - New insights into FAK phosphorylation based on a FAT domain-defective mutation JO - PLoS One VL - 9 ID - Fang2014 ER - TY - JOUR AU - Mitra, S. K. AU - Hanson, D. A. AU - Schlaepfer, D. D. PY - 2005 DA - 2005// TI - Focal adhesion kinase: in command and control of cell motility JO - Nat Rev Mol Cell Biol VL - 6 UR - https://doi.org/10.1038/nrm1549 DO - 10.1038/nrm1549 ID - Mitra2005 ER - TY - JOUR AU - Haugsten, E. M. AU - Wiedlocha, A. AU - Olsnes, S. AU - Wesche, J. PY - 2010 DA - 2010// TI - Roles of fibroblast growth factor receptors in carcinogenesis JO - Mol Cancer Res VL - 8 UR - https://doi.org/10.1158/1541-7786.MCR-10-0168 DO - 10.1158/1541-7786.MCR-10-0168 ID - Haugsten2010 ER - TY - JOUR AU - Farrell, B. AU - Breeze, A. L. PY - 2018 DA - 2018// TI - Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting JO - Biochem Soc Trans VL - 46 UR - https://doi.org/10.1042/BST20180004 DO - 10.1042/BST20180004 ID - Farrell2018 ER - TY - JOUR AU - Terai, H. AU - Soejima, K. AU - Yasuda, H. AU - Nakayama, S. AU - Hamamoto, J. AU - Arai, D. PY - 2013 DA - 2013// TI - Activation of the FGF2-FGFR1 Autocrine pathway: a novel mechanism of acquired resistance to Gefitinib in NSCLC JO - Mol Cancer Res VL - 11 UR - https://doi.org/10.1158/1541-7786.MCR-12-0652 DO - 10.1158/1541-7786.MCR-12-0652 ID - Terai2013 ER - TY - STD TI - Hatlen MA, Schmidt-Kittler O, Sherwin CA, Rozsahegyi E, Rubin N, Sheets MP, et al. Acquired on-target clinical resistance validates FGFR4 as a driver of hepatocellular carcinoma. Cancer Discov. 2019;9:1–10. https://doi.org/10.1158/2159-8290.CD-19-0367. ID - ref45 ER - TY - JOUR AU - Kim, R. i. c. h. a. r. d. D. AU - Sarker, D. e. b. a. s. h. i. s. AU - Meyer, T. i. m. AU - Yau, T. h. o. m. a. s. AU - Macarulla, T. e. r. e. s. a. AU - Park, J. o. o. n. g. -. W. o. n. AU - Choo, S. u. P. i. n. AU - Hollebecque, A. n. t. o. i. n. e. AU - Sung, M. a. x. W. AU - Lim, H. o. -. Y. e. o. n. g. AU - Mazzaferro, V. i. n. c. e. n. z. o. AU - Trojan, J. o. e. r. g. AU - Zhu, A. n. d. r. e. w. X. AU - Yoon, J. u. n. g. -. H. w. a. n. AU - Sharma, S. u. n. i. l. AU - Lin, Z. h. o. n. g. -. Z. h. e. AU - Chan, S. t. e. p. h. e. n. L. AU - Faivre, S. a. n. d. r. i. n. e. AU - Feun, L. y. n. n. G. AU - Yen, C. h. i. a. -. J. u. i. AU - Dufour, J. e. a. n. -. F. r. a. n. c. o. i. s. AU - Palmer, D. a. n. i. e. l. H. AU - Llovet, J. o. s. e. p. M. AU - Manoogian, M. e. l. i. s. s. a. AU - Tugnait, M. e. e. r. a. AU - Stransky, N. i. c. o. l. a. s. AU - Hagel, M. a. r. g. i. t. AU - Kohl, N. a. n. c. y. E. AU - Lengauer, C. h. r. i. s. t. o. p. h. AU - Sherwin, C. o. r. i. A. n. n. AU - Schmidt-Kittler, O. l. e. g. AU - Hoeflich, K. l. a. u. s. P. AU - Shi, H. o. n. g. l. i. a. n. g. AU - Wolf, B. e. n. i. B. AU - Kang, Y. o. o. n. -. K. o. o. PY - 2019 DA - 2019// TI - First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma JO - Cancer Discovery VL - 9 UR - https://doi.org/10.1158/2159-8290.CD-19-0555 DO - 10.1158/2159-8290.CD-19-0555 ID - Kim2019 ER - TY - JOUR AU - Roberts, W. G. AU - Ung, E. AU - Whalen, P. AU - Cooper, B. AU - Hulford, C. AU - Autry, C. PY - 2008 DA - 2008// TI - Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271 JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-07-5155 DO - 10.1158/0008-5472.CAN-07-5155 ID - Roberts2008 ER - TY - JOUR AU - Kolev, V. N. AU - Tam, W. F. AU - Wright, Q. G. AU - McDermott, S. P. AU - Vidal, C. M. AU - Shapiro, I. M. PY - 2017 DA - 2017// TI - Inhibition of FAK kinase activity preferentially targets cancer stem cells JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.18517 DO - 10.18632/oncotarget.18517 ID - Kolev2017 ER - TY - JOUR AU - Lark, A. L. AU - Livasy, C. A. AU - Dressler, L. AU - Moore, D. T. AU - Millikan, R. C. AU - Geradts, J. PY - 2005 DA - 2005// TI - High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype JO - Mod Pathol VL - 18 UR - https://doi.org/10.1038/modpathol.3800424 DO - 10.1038/modpathol.3800424 ID - Lark2005 ER - TY - JOUR AU - Park, J. H. AU - Lee, B. -. L. AU - Yoon, J. AU - Kim, J. AU - Kim, M. A. AU - Yang, H. -. K. PY - 2010 DA - 2010// TI - Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer JO - Hum Pathol VL - 41 UR - https://doi.org/10.1016/j.humpath.2010.06.004 DO - 10.1016/j.humpath.2010.06.004 ID - Park2010 ER - TY - JOUR AU - Dy, G. K. AU - Ylagan, L. AU - Pokharel, S. AU - Miller, A. AU - Brese, E. AU - Bshara, W. PY - 2014 DA - 2014// TI - The prognostic significance of focal adhesion kinase expression in stage I non–small-cell lung cancer JO - J Thorac Oncol VL - 9 UR - https://doi.org/10.1097/JTO.0000000000000248 DO - 10.1097/JTO.0000000000000248 ID - Dy2014 ER - TY - JOUR AU - Jones, S. F. AU - Siu, L. L. AU - Bendell, J. C. AU - Cleary, J. M. AU - Razak, A. R. A. AU - Infante, J. R. PY - 2015 DA - 2015// TI - A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors JO - Investig New Drugs VL - 33 UR - https://doi.org/10.1007/s10637-015-0282-y DO - 10.1007/s10637-015-0282-y ID - Jones2015 ER - TY - JOUR AU - Gao, J. AU - Li, H. -. R. AU - Jin, C. AU - Jiang, J. -. H. AU - Ding, J. -. Y. PY - 2019 DA - 2019// TI - Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer JO - Clinical and Translational Oncology VL - 21 UR - https://doi.org/10.1007/s12094-019-02075-1 DO - 10.1007/s12094-019-02075-1 ID - Gao2019 ER - TY - JOUR AU - Yang, Z. AU - Tam, K. Y. PY - 2018 DA - 2018// TI - Combination strategies using EGFR-TKi in NSCLC therapy: learning from the gap between pre-clinical results and clinical outcomes JO - Int J Biol Sci VL - 14 UR - https://doi.org/10.7150/ijbs.22955 DO - 10.7150/ijbs.22955 ID - Yang2018 ER - TY - JOUR AU - Wang, B. AU - Qi, X. AU - Li, D. AU - Feng, M. AU - Meng, X. AU - Fu, S. PY - 2016 DA - 2016// TI - Expression of pY397 FAK promotes the development of non-small cell lung cancer JO - Oncol Lett VL - 11 UR - https://doi.org/10.3892/ol.2015.3992 DO - 10.3892/ol.2015.3992 ID - Wang2016 ER -